Okawa Yukari, Mitsuhashi Toshiharu, Suzuki Etsuji
Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa, 765-8503, Japan.
Clinical Research Institute, Ohara HealthCare Foundation, 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan.
Clin Exp Nephrol. 2025 May;29(5):560-572. doi: 10.1007/s10157-024-02601-8. Epub 2024 Dec 6.
The relationship between serum aspartate/alanine aminotransferase ratio (AST/ALT) and subsequent development of chronic kidney disease (CKD) in non-diabetic Asian adults has not yet been fully investigated in longitudinal studies.
The study included all middle-aged and older non-diabetic Japanese citizens who received health check-ups in Zentsuji, Kagawa, Japan (1998-2023). AST/ALT was classified into three categories: < 1.0 (reference), 1.0- < 1.5, and ≥ 1.5. CKD was defined as an estimated glomerular filtration rate of < 60 mL/min/1.73 m. The Weibull accelerated failure time model was used to examine the association between AST/ALT categories and subsequent CKD onset because the proportional hazards assumption was violated.
Of 6309 men and 9192 women, 2966 men and 4395 women remained in the final cohort. After a mean follow-up of 7.50 years for men and 8.34 years for women, 33.7% of men and 34.0% of women developed CKD. Women had higher AST/ALT than men. In women, a dose-response relationship was observed, with a 9% shorter survival time to CKD onset for AST/ALT ≥ 1.5 compared with AST/ALT < 1.0. In contrast, men had a shorter survival time to CKD onset by point estimates, but the 95% confidence intervals crossed 1 in all models.
In this study comparing the risks of CKD development in non-diabetic men and women by AST/ALT levels, a dose-response relationship was only observed in women. Differences in the distribution of AST/ALT by sex may have affected the results. Therefore, in non-diabetic Japanese women, AST/ALT may be used as an indicator of future CKD development.
在非糖尿病亚洲成年人中,血清天冬氨酸/丙氨酸转氨酶比值(AST/ALT)与慢性肾脏病(CKD)后续发生之间的关系在纵向研究中尚未得到充分调查。
该研究纳入了在日本香川县善通寺接受健康检查的所有中老年非糖尿病日本公民(1998 - 2023年)。AST/ALT分为三类:<1.0(参照)、1.0 - <1.5和≥1.5。CKD定义为估算肾小球滤过率<60 mL/min/1.73 m²。由于违反了比例风险假设,因此使用威布尔加速失效时间模型来检验AST/ALT类别与后续CKD发病之间的关联。
在6309名男性和9192名女性中,最终队列中有2966名男性和4395名女性。男性平均随访7.50年,女性平均随访8.34年,33.7%的男性和34.0%的女性发生了CKD。女性的AST/ALT高于男性。在女性中,观察到剂量反应关系,与AST/ALT<1.0相比,AST/ALT≥1.5的女性发生CKD的生存时间缩短9%。相比之下,男性发生CKD的生存时间按点估计较短,但在所有模型中95%置信区间均跨过1。
在本研究中,通过AST/ALT水平比较非糖尿病男性和女性发生CKD的风险,仅在女性中观察到剂量反应关系。AST/ALT在性别上的分布差异可能影响了结果。因此,在非糖尿病日本女性中,AST/ALT可作为未来CKD发生的一个指标。